Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 140 of the 142 references it cites were found in a registry or an index; 38 of the 122 sources its claims cite were checked for support.

The design and development of covalent protein-protein interaction inhibitors for cancer treatment

Open access
Cheng, Sha-Sha, Yang, Guan-Jun, Wang, Wanhe, Leung, Chung-Hang, Ma, Dik-Lung · 2020 · Journal of Hematology & Oncology

Abstract

Protein-protein interactions (PPIs) are central to a variety of biological processes, and their dysfunction is implicated in the pathogenesis of a range of human diseases, including cancer. Hence, the inhibition of PPIs has attracted significant attention in drug discovery. Covalent inhibitors have been reported to achieve high efficiency through forming covalent bonds with cysteine or other nucleophilic residues in the target protein. Evidence suggests that there is a reduced risk for the development of drug resistance against covalent drugs, which is a major challenge in areas such as oncology and infectious diseases. Recent improvements in structural biology and chemical reactivity have enabled the design and development of potent and selective covalent PPI inhibitors. In this review, we will highlight the design and development of therapeutic agents targeting PPIs for cancer therapy.

Overview

CoChat Summary

TL;DR

This review discusses the design and development of covalent protein–protein interaction (PPI) inhibitors for cancer, covering structure-guided design, activity-based protein profiling, covalent docking, and screening strategies. It argues that covalent PPI inhibitors can provide durable inhibition and reduced resistance risk, but face challenges including off-target toxicity, immunogenicity, and metabolic liabilities.

Key findings

  • PPIs are central to cancer biology: there are nearly 650,000 PPIs in humans, 20% of proteins exist in network hubs and interact with at least 24 partners, and PPI hotspots typically span 250–900 Ų while small-molecule PPI interfaces are often 1500–3000 Ų.
  • Covalent PPI inhibitors form covalent bonds with cysteine or other nucleophilic residues and can offer sustained inhibition, longer residence times, high selectivity, and a reduced risk of drug resistance; drawbacks include off-target toxicity, potential immunogenicity, reactive metabolite formation, and poor pharmacokinetics such as high clearance.
  • Design and discovery strategies include structure-guided design, activity-based protein profiling (including isoTOP-ABPP), covalent docking programs such as MOE, CovDock, AutoDock4, FITTED, GOLD, and ICM-Pro, and screening methods including fragment-based screening, high-throughput screening, phenotypic screening, and quantitative irreversible tethering (qIT) with fluorogenic thiol quantification.
  • Examples in cancer include COH000 targeting SUMO E1 with anticancer activity in colorectal cancer cells and mouse/patient-derived xenograft models, TED-347 allosterically targeting the TEAD–Yap PPI, a covalent Mcl-1 inhibitor reacting with Lys234, the Grb2–Sos1 peptide inhibitor targeting Cys32, and THZ531 inhibiting CDK12–CDK13; the review states that one covalent PPI inhibitor has been approved by the FDA in oncology while others have entered clinical trials.

Methods

  • This is a narrative review, not a primary research study; no experimental design, sample, or dataset is reported.
  • It synthesizes literature on covalent PPI inhibitor design and development for cancer, including structure-guided design, ABPP, covalent docking, screening technologies, and tables of successful covalent PPI inhibitors and non-covalent PPI candidates in cancer.
  • The main analysis is qualitative and descriptive, with no systematic search strategy or quantitative meta-analysis described.

Limitations

  • Stated in the paper: isoTOP-ABPP is limited by the range of identifiable cellular cysteines and cannot evaluate compound selectivity across the total cellular cysteinome; cell lysates under non-reducing conditions may oxidize or aggregate reactive cysteines. Covalent docking suffers from poor scoring functions and limitations in torsional entropy, speed, and accuracy, and requires substantial preparatory work not easily automated. Covalent inhibitors can cause off-target toxicity, immunogenicity, reactive metabolites, and high clearance, and their pharmacological and toxicological mechanisms remain unclear.
  • Evident from the text: as a narrative review, it does not provide a systematic or exhaustive search protocol, and the examples and tables are selected illustrations rather than a comprehensive quantitative synthesis.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s13045-020-00850-0

Cites

140 of 140 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Oncogenic PPI networks that are associated with the hallmarks of tumorigenesis. It should be noted that some PPI networks regulate global mechanisms of cell growth and their relationship to cancer remains to be verified
Fig. 1 Oncogenic PPI networks that are associated with the hallmarks of tumorigenesis. It should be noted that some PPI networks regulate global mechanisms of cell growth and their relationship to cancer remains to be verifiedCC BY · PubMed Central
Fig. 2 The crystal structure of three different classes of PPIs. a Linear sequences comprise primary peptide epitopes (e.g., LM of DNA polymerase III bound to the binding pocket of the SC (PDB: 3D1F)). b The secondary structure of epitopes binds as a single unit, e.g., an α-helix (NusB-NusE PPI (PDB: 3R2C)). c In tertiary structural epitopes, the binding interface is not continuous and both sides of PPI interface are needed (e.g., IL-2/IL-2Ra PPI (PDB 1Z92))
Fig. 2 The crystal structure of three different classes of PPIs. a Linear sequences comprise primary peptide epitopes (e.g., LM of DNA polymerase III bound to the binding pocket of the SC (PDB: 3D1F)). b The secondary structure of epitopes binds as a single unit, e.g., an α-helix (NusB-NusE PPI (PDB: 3R2C)). c In tertiary structural epitopes, the binding interface is not continuous and both sides of PPI interface are needed (e.g., IL-2/IL-2Ra PPI (PDB 1Z92))CC BY · PubMed Central
Fig. 3 The general workflow of the isoTOP-ABPP platform. The cell proteome is labeled with a cysteine-reactive probe, and then samples are conjugated to TEV protease-cleavable biotin tags (heavy (blue) and light (red)). Competition ratios are calculated following protein digestion and multidimensional liquid chromatography-tandem mass spectrometry
Fig. 3 The general workflow of the isoTOP-ABPP platform. The cell proteome is labeled with a cysteine-reactive probe, and then samples are conjugated to TEV protease-cleavable biotin tags (heavy (blue) and light (red)). Competition ratios are calculated following protein digestion and multidimensional liquid chromatography-tandem mass spectrometryCC BY · PubMed Central
Fig 4 General scheme describing the workflow of covalent docking in drug discovery
Fig 4 General scheme describing the workflow of covalent docking in drug discoveryCC BY · PubMed Central
Fig. 5 The workflow of the qIT assay. The thiol is challenged with electrophiles under pseudo-first-order conditions in the presence of TCEP. The reaction progress is monitored by analyzing residual thiol concentration using the fluorogenic probe CPM
Fig. 5 The workflow of the qIT assay. The thiol is challenged with electrophiles under pseudo-first-order conditions in the presence of TCEP. The reaction progress is monitored by analyzing residual thiol concentration using the fluorogenic probe CPMCC BY · PubMed Central
Fig. 6 The covalent inhibitor TED-347 inhibits the TEAD-Yap PPI in allosteric formation by targeting a conserved cysteine within the palmitate pocket of TEAD
Fig. 6 The covalent inhibitor TED-347 inhibits the TEAD-Yap PPI in allosteric formation by targeting a conserved cysteine within the palmitate pocket of TEADCC BY · PubMed Central
Fig. 7 The equations for the target-specific action of covalent inhibitors. E: enzyme target, I: inhibitor, kinact: rate of inactivation of the target, k2: rate of the subsequent bond-forming reaction, KI: inhibition constant
Fig. 7 The equations for the target-specific action of covalent inhibitors. E: enzyme target, I: inhibitor, kinact: rate of inactivation of the target, k2: rate of the subsequent bond-forming reaction, KI: inhibition constantCC BY · PubMed Central

Verification

Claims the paper makes

15 Valid · 3 Not valid · 55 Not checked · 10 Own results and interpretations

50 more claims · 9 with their cited sources checked

Create a free account to see all 83 claims and to verify the 84 references still open.

See all claims — free account
  • Probably not a substantial claim. 11
  • It may state two separate claims as one. 21

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 142 references

Cited by

See all 111

Metadata

Authors
Cheng, S.-S., Yang, G.-J., Wang, W., Leung, C.-H., & Ma, D.-L.
Affiliations
  • University of Macau (MO)
  • Hong Kong Baptist University (HK)
Corresponding author
  • Leung, Chung-Hang
  • Ma, Dik-Lung
Venue
Journal of Hematology & Oncology
Published
2020-03-30
Volume
13
Issue
1
Pages
26-26
ISSN
1756-8722 (ISSN-L)
OpenAlex
W3013096229
Cited by
98
References
142
Citations by year
2026: 12 · 2025: 13 · 2024: 20 · 2023: 13 · 2022: 16 · 2021: 19 · 2020: 5
FWCI
1.29
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Hematology & Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Hong Kong Baptist University (C5026-16G, RC-IRCS-17-18/03, FRG2/17, RC-IRMS/16-17/03, SKLP_1920_P02)
  • National Natural Science Foundation of China (21575121, 21775131)
  • Universidade de Macau (MYRG2018–00187–ICMS, MYRG2019-00002-ICMS and MYRG2018-00187-ICMS, MYRG2019-00002-ICMS)
  • Health and Medical Research Fund (14150561, HMRF / 14150561)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
  • Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
Keywords
protein-protein interaction inhibitors, covalent inhibitors, cancer therapy, drug resistance, inhibitor design, anticancer drug discovery
MeSH terms
Drug Development, Animals, Antineoplastic Agents, Humans, Models, Molecular, Neoplasms, Drug Design, Protein Interaction Maps

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The design and development of covalent protein-protein interaction inhibitors for cancer treatment. https://app.cochat.ai/papers/10.1186/s13045-020-00850-0
The paper
Cheng, S.-S., Yang, G.-J., Wang, W., Leung, C.-H., & Ma, D.-L. (2020). The design and development of covalent protein-protein interaction inhibitors for cancer treatment. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-020-00850-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.